Literature DB >> 26103984

Natriuretic Peptides and Cardiometabolic Health.

Deepak K Gupta1, Thomas J Wang.   

Abstract

Natriuretic peptides are cardiac-derived hormones with a range of protective functions, including natriuresis, diuresis, vasodilation, lusitropy, lipolysis, weight loss, and improved insulin sensitivity. Their actions are mediated through membrane-bound guanylyl cyclases that lead to production of the intracellular second-messenger cyclic guanosine monophosphate. A growing body of evidence demonstrates that genetic and acquired deficiencies of the natriuretic peptide system can promote hypertension, cardiac hypertrophy, obesity, diabetes mellitus, the metabolic syndrome, and heart failure. Clinically, natriuretic peptides are robust diagnostic and prognostic markers, and augmenting natriuretic peptides is a target for therapeutic strategies in cardiometabolic disease. This review will summarize current understanding and highlight novel aspects of natriuretic peptide biology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26103984      PMCID: PMC4893202          DOI: 10.1253/circj.CJ-15-0589

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  138 in total

1.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Authors:  Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

2.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

3.  Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts.

Authors:  L Cao; D G Gardner
Journal:  Hypertension       Date:  1995-02       Impact factor: 10.190

4.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 5.  Molecular physiology of natriuretic peptide signalling.

Authors:  Michaela Kuhn
Journal:  Basic Res Cardiol       Date:  2004-01-23       Impact factor: 17.165

6.  Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption.

Authors:  P J Harris; D Thomas; T O Morgan
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  Natriuretic peptides enhance the oxidative capacity of human skeletal muscle.

Authors:  Stefan Engeli; Andreas L Birkenfeld; Pierre-Marie Badin; Virginie Bourlier; Katie Louche; Nathalie Viguerie; Claire Thalamas; Emilie Montastier; Dominique Larrouy; Isabelle Harant; Isabelle de Glisezinski; Stefanie Lieske; Julia Reinke; Bibiana Beckmann; Dominique Langin; Jens Jordan; Cedric Moro
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

8.  Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study.

Authors:  David Conen; Suzanne Cheng; Lori L Steiner; Julie E Buring; Paul M Ridker; Robert Y L Zee
Journal:  J Hypertens       Date:  2009-03       Impact factor: 4.844

9.  Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney.

Authors:  M Marin-Grez; J T Fleming; M Steinhausen
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

10.  The gene encoding atrial natriuretic peptide and the risk of human stroke.

Authors:  S Rubattu; P Ridker; M J Stampfer; M Volpe; C H Hennekens; K Lindpaintner
Journal:  Circulation       Date:  1999-10-19       Impact factor: 29.690

View more
  21 in total

1.  NT-proBNP, race and endothelial function in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Sushan Yang; Shi Huang; Lori B Daniels; Joseph Yeboah; Joao A C Lima; Valentina Cannone; John C Burnett; Joshua A Beckman; J Jeffrey Carr; Thomas J Wang; Deepak K Gupta
Journal:  Heart       Date:  2019-05-31       Impact factor: 5.994

Review 2.  Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.

Authors:  Sanjiv J Shah
Journal:  J Cardiovasc Transl Res       Date:  2017-06-05       Impact factor: 4.132

Review 3.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

Review 4.  NT-proBNP Concentrations in the Umbilical Cord and Serum of Term Neonates: A Systematic Review and Meta-Analysis.

Authors:  Evangelos Christou; Zoe Iliodromiti; Abraham Pouliakis; Rozeta Sokou; Matina Zantiotou; Chrisa Petropoulou; Theodora Boutsikou; Nicoletta Iacovidou
Journal:  Diagnostics (Basel)       Date:  2022-06-08

5.  Cardiac cycle time-corrected electromechanical activation time greater than 15% is an independent risk factor for major adverse cardiovascular events in chronic heart failure outpatients.

Authors:  Jing Zhang; Wenxian Liu
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

6.  Impact of diabetes on the predictive value of heart failure biomarkers.

Authors:  Nuria Alonso; Josep Lupón; Jaume Barallat; Marta de Antonio; Mar Domingo; Elisabet Zamora; Pedro Moliner; Amparo Galán; Javier Santesmases; Cruz Pastor; Dídac Mauricio; Antoni Bayes-Genis
Journal:  Cardiovasc Diabetol       Date:  2016-11-03       Impact factor: 9.951

Review 7.  Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.

Authors:  Javier Díez
Journal:  Eur J Heart Fail       Date:  2016-10-21       Impact factor: 15.534

8.  Prenatal Particulate Matter (PM) Exposure and Natriuretic Peptides in Newborns from Mexico City.

Authors:  Abigail Muñoz-Rodríguez; Jorge Alfonso Maciel-Ruiz; Ana María Salazar; Monserrat Sordo; Patricia Ostrosky-Wegman; Jorge H Limón-Pacheco; Andrés Eduardo Nepomuceno-Hernández; Rodrigo Ayala-Yáñez; María Eugenia Gonsebatt; Citlalli Osorio-Yáñez
Journal:  Int J Environ Res Public Health       Date:  2021-06-18       Impact factor: 3.390

9.  Proposal for heart failure progression based on the 'chloride theory': worsening heart failure with increased vs. non-increased serum chloride concentration.

Authors:  Hajime Kataoka
Journal:  ESC Heart Fail       Date:  2017-07-17

Review 10.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.

Authors:  Shihui Fu; Ping Ping; Fengqi Wang; Leiming Luo
Journal:  J Biol Eng       Date:  2018-01-12       Impact factor: 4.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.